Immunothérapie des cancers : une lueur au bout du tunnel ?

Guillaume Darrasse-Jèze; David Klatzmann

doi:10.1051/medsci/20112710001

Accueil

Tous les numéros

Volume 27 / Numéro 10 (Octobre 2011)

Med Sci (Paris), 27 10 (2011) 795-797

Références

Accès gratuit

Editorial

Numéro		Med Sci (Paris) Volume 27, Numéro 10, Octobre 2011


Page(s)		795 - 797
Section		Éditorial
DOI		https://doi.org/10.1051/medsci/20112710001
Publié en ligne		21 octobre 2011

Tartour E, Fridman WH, Bonnefoy JY, Sandoval F. Immunothérapie des cancers : succès récents et futures directions. Med Sci (Paris) 2011 ; 27 : 833–841. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004 ; 10 : 909–915. [CrossRef] [PubMed] [Google Scholar]
Chouaib S, El Hage F, Benlalam H, Mami-Chouaib F. Immunothérapie du cancer : espoirs et réalités. Med Sci (Paris) 2006 ; 22 : 755–759. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
Sawyers C. Targeted cancer therapy. Nature 2004 ; 432 : 294–297. [CrossRef] [PubMed] [Google Scholar]
Kaiser J. Combining targeted drugs to stop resistant tumors. Science 2011 ; 331 : 1542–1545. [CrossRef] [PubMed] [Google Scholar]
Sakaguchi S, Wing K, Onishi Y, et al. Regulatory T cells: how do they suppress immune responses? Int Immunol 2009 ; 21 : 1105–1111. [CrossRef] [PubMed] [Google Scholar]
Nishikawa H, Sakaguchi S. Regulatory cells in tumor immunity. Int J Cancer 2010; 127 : 759–767. [PubMed] [Google Scholar]
Poschke I, Mougiakakos D, Kiessling R.. Camouflage and sabotage: tumor escape from the immune system. Cancer Immunol Immunother 2011 ; 60 : 1161–1171. [CrossRef] [PubMed] [Google Scholar]
Chaput N, Darrasse-Jeze G, Bergot AS, et al. Regulatory T cells prevent CD8 T cell maturation by inhibiting CD4 Th cells at tumor sites. J Immunol 2007 ; 179 : 4969–4978. [PubMed] [Google Scholar]
Ladoire S, Martin F, Ghiringhelli F. Prognostic role of FOXP3⁺ regulatory T cells infiltrating human carcinomas: the paradox of colorectal cancer. Cancer Immunol Immunother 2011 ; 60 : 909–918. [CrossRef] [PubMed] [Google Scholar]
Onizuka S, Tawara I, Shimizu J, et al. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res 1999 ; 59 : 3128–3133. [PubMed] [Google Scholar]
Golgher D, Jones E, Powrie F, et al. Depletion of CD25⁺ regulatory cells uncovers immune responses to shared murine tumor rejection antigens. Eur J Immunol 2002 ; 32 : 3267–3275. [CrossRef] [PubMed] [Google Scholar]
Teng MW, Swann JB, von Scheidt B, et al. Multiple antitumor mechanisms downstream of prophylactic regulatory T-cell depletion. Cancer Res 2010 ; 70 : 2665–2674. [CrossRef] [PubMed] [Google Scholar]
Darrasse-Jeze G, Bergot AS, Durgeau A, et al. Tumor emergence is sensed by self-specific CD44hi memory Tregs that create a dominant tolerogenic environment for tumors in mice. J Clin Invest 2009 ; 119 : 2648–2662. [PubMed] [Google Scholar]
Maury S, Lemoine FM, Hicheri Y, et al. CD4⁺CD25⁺ regulatory T cell depletion improves the graft-versus-tumor effect of donor lymphocytes after allogeneic hematopoietic stem cell transplantation. Sci Transl Med 2011 ; 2 : 41–52. [Google Scholar]
Porter DL, Levine BL, Kalos M, et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011 ; 365 : 725–733. [CrossRef] [PubMed] [Google Scholar]
Kalos M, Levine BL, Porter DL, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011 ; 3 : 95–73. [CrossRef] [Google Scholar]
Zitvogel L, Kepp O, Kroemer G. Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol 2011 ; 8 : 151–160. [CrossRef] [PubMed] [Google Scholar]
Peggs KS, Quezada SA, Chambers CA, et al. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med 2009 ; 206 : 1717–1725. [CrossRef] [PubMed] [Google Scholar]
Wing K, Onishi Y, Prieto-Martin P, et al. CTLA-4 control over Foxp3⁺ regulatory T cell function. Science 2008 ; 322 : 271–275. [CrossRef] [PubMed] [Google Scholar]
Menard C, Ghiringhelli F, Roux S, et al. CTLA-4 blockade confers lymphocyte resistance to regulatory T-cells in advanced melanoma: surrogate marker of efficacy of tremelimumab? Clin Cancer Res 2008 ; 14 : 5242–5249. [CrossRef] [PubMed] [Google Scholar]
Chambers CA, Kuhns MS, Egen JG, Allison JP. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol 2001 ; 19 : 565–594. [CrossRef] [PubMed] [Google Scholar]
Olive D, le Thi S, Xerri L, et al. Rôle de CTLA-4 dans la cosignalisation négative du systeme immunitaire. Med Sci (Paris) 2011 ; 27 : 842–849. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
Robert C, Mateus C. Anticorps anti-CTLA-4 : une avancée thérapeutique majeure dans le traitement du mélanome metastatique. Med Sci (Paris) 2011 ; 27 : 850–858. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.

[1] Tartour E, Fridman WH, Bonnefoy JY, Sandoval F. Immunothérapie des cancers : succès récents et futures directions. Med Sci (Paris) 2011 ; 27 : 833–841. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]

[2] Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004 ; 10 : 909–915. [CrossRef] [PubMed] [Google Scholar]

[3] Chouaib S, El Hage F, Benlalam H, Mami-Chouaib F. Immunothérapie du cancer : espoirs et réalités. Med Sci (Paris) 2006 ; 22 : 755–759. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]

[4] Sawyers C. Targeted cancer therapy. Nature 2004 ; 432 : 294–297. [CrossRef] [PubMed] [Google Scholar]

[5] Kaiser J. Combining targeted drugs to stop resistant tumors. Science 2011 ; 331 : 1542–1545. [CrossRef] [PubMed] [Google Scholar]

[6] Sakaguchi S, Wing K, Onishi Y, et al. Regulatory T cells: how do they suppress immune responses? Int Immunol 2009 ; 21 : 1105–1111. [CrossRef] [PubMed] [Google Scholar]

[7] Nishikawa H, Sakaguchi S. Regulatory cells in tumor immunity. Int J Cancer 2010; 127 : 759–767. [PubMed] [Google Scholar]

[8] Poschke I, Mougiakakos D, Kiessling R.. Camouflage and sabotage: tumor escape from the immune system. Cancer Immunol Immunother 2011 ; 60 : 1161–1171. [CrossRef] [PubMed] [Google Scholar]

[9] Chaput N, Darrasse-Jeze G, Bergot AS, et al. Regulatory T cells prevent CD8 T cell maturation by inhibiting CD4 Th cells at tumor sites. J Immunol 2007 ; 179 : 4969–4978. [PubMed] [Google Scholar]

[10] Ladoire S, Martin F, Ghiringhelli F. Prognostic role of FOXP3⁺ regulatory T cells infiltrating human carcinomas: the paradox of colorectal cancer. Cancer Immunol Immunother 2011 ; 60 : 909–918. [CrossRef] [PubMed] [Google Scholar]

[11] Onizuka S, Tawara I, Shimizu J, et al. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res 1999 ; 59 : 3128–3133. [PubMed] [Google Scholar]

[12] Golgher D, Jones E, Powrie F, et al. Depletion of CD25⁺ regulatory cells uncovers immune responses to shared murine tumor rejection antigens. Eur J Immunol 2002 ; 32 : 3267–3275. [CrossRef] [PubMed] [Google Scholar]

[13] Teng MW, Swann JB, von Scheidt B, et al. Multiple antitumor mechanisms downstream of prophylactic regulatory T-cell depletion. Cancer Res 2010 ; 70 : 2665–2674. [CrossRef] [PubMed] [Google Scholar]

[14] Darrasse-Jeze G, Bergot AS, Durgeau A, et al. Tumor emergence is sensed by self-specific CD44hi memory Tregs that create a dominant tolerogenic environment for tumors in mice. J Clin Invest 2009 ; 119 : 2648–2662. [PubMed] [Google Scholar]

[15] Maury S, Lemoine FM, Hicheri Y, et al. CD4⁺CD25⁺ regulatory T cell depletion improves the graft-versus-tumor effect of donor lymphocytes after allogeneic hematopoietic stem cell transplantation. Sci Transl Med 2011 ; 2 : 41–52. [Google Scholar]

[16] Porter DL, Levine BL, Kalos M, et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011 ; 365 : 725–733. [CrossRef] [PubMed] [Google Scholar]

[17] Kalos M, Levine BL, Porter DL, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011 ; 3 : 95–73. [CrossRef] [Google Scholar]

[18] Zitvogel L, Kepp O, Kroemer G. Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol 2011 ; 8 : 151–160. [CrossRef] [PubMed] [Google Scholar]

[19] Peggs KS, Quezada SA, Chambers CA, et al. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med 2009 ; 206 : 1717–1725. [CrossRef] [PubMed] [Google Scholar]

[20] Wing K, Onishi Y, Prieto-Martin P, et al. CTLA-4 control over Foxp3⁺ regulatory T cell function. Science 2008 ; 322 : 271–275. [CrossRef] [PubMed] [Google Scholar]

[21] Menard C, Ghiringhelli F, Roux S, et al. CTLA-4 blockade confers lymphocyte resistance to regulatory T-cells in advanced melanoma: surrogate marker of efficacy of tremelimumab? Clin Cancer Res 2008 ; 14 : 5242–5249. [CrossRef] [PubMed] [Google Scholar]

[22] Chambers CA, Kuhns MS, Egen JG, Allison JP. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol 2001 ; 19 : 565–594. [CrossRef] [PubMed] [Google Scholar]

[23] Olive D, le Thi S, Xerri L, et al. Rôle de CTLA-4 dans la cosignalisation négative du systeme immunitaire. Med Sci (Paris) 2011 ; 27 : 842–849. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]

[24] Robert C, Mateus C. Anticorps anti-CTLA-4 : une avancée thérapeutique majeure dans le traitement du mélanome metastatique. Med Sci (Paris) 2011 ; 27 : 850–858. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]